PremiumCompany AnnouncementsFulcrum Therapeutics Reports Strong Financial Position and Progress OpCo reiterates Outperform on Fulcrum given bullish vibes ahead of SCD readout Fulcrum Therapeutics reports Q4 EPS (31c), consensus (29c) PremiumThe FlyFulcrum Therapeutics rumor highlighted in Betaville alert Biotech Alert: Searches spiking for these stocks today Fulcrum Therapeutics Reports Q3 2024 Financial Progress PremiumThe FlyLeerink sees little impact to genetic medicines from Pfizer’s Oxbryta withdrawal Fulcrum Therapeutics to reduce workforce from 80 to 51 full-time employees Largest borrow rate increases among liquid names 
